Our Purpose is the sustainable improvement of global animal health and welfare.
Dechra is a global specialist in veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.
We are a global leader in veterinary endocrinology and topical dermatology, have a broad portfolio of analgesia, anaesthetics and products for the treatment of pain, and we are also recognised as innovators in other specialisations such as the treatment of equine lameness, nutrition and differentiated generics.
Everything we do is underpinned by our Culture and Values. They are important to us and have helped drive the Group’s success. We believe that our Values encapsulate our business ethics and set out the standards that we wish to achieve and ultimately exceed. They outline the type of people we are, the services we provide and the way we aim to do business. We deliver high quality products and services to veterinarians worldwide through our employees and a network of third parties to sustainably improve global animal health and welfare.
Our objectives are to innovate, develop, acquire, register, manufacture, supply and market high-quality products to the veterinary profession worldwide. We also offer high levels of service, technical support and educational training to promote the Dechra brand and to develop a strong relationship with and be recognised as an important partner to, veterinarians.
Innovative Products that Treat a Range of Conditions add
Dechra develops and manufactures drugs and therapies to improve the prevention, diagnosis, care and treatment of animals.
The value created for veterinarians: Our products give veterinarians the solutions they need in the treatment of animals. The majority of Dechra’s key products are novel or have clear advantages over competitor products. This allows veterinarians to offer a high standard of care to animals that they treat.
Educational and Training Programmes add
We offer high-level educational programmes focused on the diagnosis and treatment of conditions in our key therapeutic areas. We deliver this education through many channels, including major conferences, regional groups, individual practices and increasingly through digital channels.
The value created for veterinarians: We help to improve the knowledge and education of veterinarians. These programmes are certified to offer veterinarians and veterinary nurses the continuing professional education hours they require to maintain their professional qualification.
Customer Support add
Dechra provides high levels of technical support and pharmacovigilance through helplines in every country in which we operate.
The value created for veterinarians: These helplines provide veterinarians with support on how best to use our products and free advice on any difficult or complex cases that may be encountered. This enables veterinarians to be fully informed and have the knowledge they need to apply best practice approaches to their care and treatment of animals.
How This Fulfils Our Purpose add
Our products enable the improvement of animal health and welfare. Our customer support, educational and training programmes help to inform veterinarians around the globe and further improve animal health and welfare.
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide.
add
DVP EU markets and sells Dechra’s products in 19 countries: Austria, Belgium, Bosnia & Hertz, Croatia, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden and the UK.
In total, DVP EU employs 511 people, as field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, and technical support staff. Inventory is managed through a central distribution centre in Uldum.
The key products in the DVP EU portfolio are predominantly Companion Animal Products (CAP), Equine medicines and Food producing Animal Products (FAP). DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded Specific™.
add
DVP International was established as a separate commercial division in 2017, with the aim of further developing Dechra’s global brand and product offering. It markets and sells Dechra’s veterinary products in Australia, New Zealand and Brazil through our own legal entities and via distributors to 72 countries worldwide. DVP International has 90 employees excluding those employees in the Australian and Brazilian Manufacturing facilities.
DVP ANZ was established in 2016. It manufactures, markets and sells branded non-proprietary prescription and other related companion animal products in Australia and New Zealand. Following the acquisition in 2021 of the marketing rights to Tri-Solfen, the business will establish a farm animal business unit to deliver products and support for welfare in farm animal production.
DVP Brazil was acquired in 2018. It predominately manufactures, markets and sells vaccines in Brazil, other South American markets and some Asian countries. We are currently registering Dechra’s leading companion animal brands.
Dechra International distributes its leading FAP, CAP, nutrition and poultry vaccine products to its key customers in most global markets. Through offering technical service and marketing support we help our customers establish our key brands and with the support of regulatory services we register and introduce new products to meet market needs.
add
DVP NA markets and sells Dechra’s veterinary products across Canada, Mexico and the US, the latter being the world’s largest animal health market.
The US business is located in Kansas City, at the heart of the ‘Animal Health Corridor’, an area recognised globally for its concentration of animal health businesses. There is also an additional office in Portland, Maine where part of the Product Development is based and a number of tele-sales.
DVP NA has 246 employees, who consist of field-based sales representatives, marketing professionals, in-house veterinarians, field veterinarians, technical support staff and a customer service team. DVP US and Canada currently markets CAP and Equine medicines.
DVP Canada was established in January 2015 and the office is located in Montreal.
DVP Mexico, was acquired in January 2016. It markets CAP, FAP and Equine medicines, mainly in Mexico and also exports to Central American countries.
add
The Product Development team develops Dechra’s own branded veterinary product portfolio of novel, generic and generic plus pharmaceuticals and related medical products. The Regulatory Affairs team obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licences.
A total of 159 people work across European and US Regulatory Affairs, Pharmaceutical Development and Product Development. The Regulatory Affairs team work at seven locations:
The Product Development team run in field clinical trials and formulate at three laboratories based at our manufacturing facilities.
The team includes highly qualified academics, veterinarians, formulation chemists, pharmacists, analysts, clinical trial managers and product development managers.
add
DPM produces approximately 40% of Dechra’s pharmaceuticals and manufactures for a limited number of third parties on a contract basis. It’s objectives are to produce Dechra’s product range efficiently to the highest quality standards, to maintain a reliable supply chain and to contribute profit to the business through third party manufacturing.
A total of 876 employees work in Manufacturing.
Skipton, Bladel and Zagreb sites include Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.
Skipton, UK
The site at Skipton offers a comprehensive range of manufacturing and packing services, principally for CAP. It is a centre of excellence in solid forms for tablets and capsules, liquids, creams, ointment products and terminal sterilisation.
Bladel, the Netherlands
The site at Bladel manufactures water soluble powder and premix products for food producing animals in large-scale batches. It is also a centre for aseptic filling and for sterile injectables for both FAP and CAP.
Zagreb, Croatia
It produces and develops egg based vaccines. It also produces liquids in various scales and formats and is currently being expanded to be a second source of solid dose tablets.
Fort Worth, Texas USA
This site manufactures solid dose, liquids, creams and ointments for the North American market.
Melbourne, Florida USA
It is a centre of excellence in manufacturing palatable and chewable tablets.
The following manufacturing sites are managed by our DVP International business:
Londrina, Brazil
This site produces a wide range of vaccines for multi species predominately for South America and selected export markets.
Sydney, Australia
This site produces a broad portfolio of dosage types for the Australian and New Zealand markets including tablets and liquids.
Our Values are a consistent part of how we lead the Dechra business. From recruitment through to investment in the development and growth of our employees we use our Values to describe what matters at Dechra.
As the Dechra business grows through acquisition, we have recognised the importance of onboarding new employees into the Dechra way and enabling them to share and build on our Values as a route to unlocking value and success.
We believe that our Values encapsulate our business ethics and set the standards that we wish to achieve and ultimately exceed. They outline the type of people we are, the services we provide and the way we aim to do business.
0 results Searching...
apps Products (0)
